137 related articles for article (PubMed ID: 38544442)
1. Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option.
Greene A; Penner S; Kunesh J; Altaf A; McGrade W; Niu J
J Oncol Pharm Pract; 2024 Mar; ():10781552241241493. PubMed ID: 38544442
[TBL] [Abstract][Full Text] [Related]
2. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
Ishiguro A; Ogata D; Ohashi K; Hiki K; Yamakawa K; Jinnai S; Tsutsui K; Takahashi A; Namikawa K; Yamazaki N
Medicine (Baltimore); 2022 Sep; 101(35):e30398. PubMed ID: 36107581
[TBL] [Abstract][Full Text] [Related]
3. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract][Full Text] [Related]
4. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
Hilder R; Tsai K; Quandt Z; Isaacs D; Drakaki A; Xing Y; In GK; Angell TE; Lechner MG
Front Endocrinol (Lausanne); 2023; 14():1242830. PubMed ID: 38027216
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Xu C; Chen YP; Du XJ; Liu JQ; Huang CL; Chen L; Zhou GQ; Li WF; Mao YP; Hsu C; Liu Q; Lin AH; Tang LL; Sun Y; Ma J
BMJ; 2018 Nov; 363():k4226. PubMed ID: 30409774
[TBL] [Abstract][Full Text] [Related]
11. Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.
Gupta M; Stukalin I; Meyers D; Goutam S; Heng DYC; Cheng T; Monzon J; Navani V
JAMA Netw Open; 2023 Jun; 6(6):e2319607. PubMed ID: 37351883
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced diabetes mellitus-a case report with literature review of the treatment options.
Daetwyler E; Zippelius A; Danioth S; Donath MY; Gut L
Front Immunol; 2023; 14():1248919. PubMed ID: 37965350
[TBL] [Abstract][Full Text] [Related]
13. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
15. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance study.
Bastin M; Allouchery M; Sassier M; Rouby F; Eftekhari P; Lebrun-Vignes B; Andreelli F; Bihan K
Therapie; 2021; 76(6):695-703. PubMed ID: 33836905
[TBL] [Abstract][Full Text] [Related]
17. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
18. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
19. Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.
Motomura Y; Urai S; Hirota Y; Takegawa N; Bando H; Yamamoto M; Fukuoka H; Tsuda M; Ogawa W
Diabetol Int; 2024 Jan; 15(1):130-134. PubMed ID: 38264226
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor-Induced Pure Red Cell Aplasia: A Review of 2 Cases in Metastatic Melanoma.
Rueda Prada L; Gavrancic T; Cadena Sanabria MO; Dumic I; Bourgeois K; King RL; Yan Y
Am J Case Rep; 2023 Nov; 24():e941789. PubMed ID: 37957950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
